SINGAPORE (Feb 15): Hyflux and Changi General Hospital on Wednesday signed an agreement to conduct two clinical trials to establish the effectiveness of Hyflux’s ELO Water and ELO Gel on diabetes patients.

This will be the first time the clinical trials are conducted on humans, following “positive results” obtained from animal trials of ELO Water conducted overseas.

Dr Joan Khoo, senior consultant and chief of endocrinology at CGH, is the principal investigator of the trials.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook